Filing summary
Entity and period: The supplied filing is First Wave BioPharma, Inc.’s Form 10-K for the fiscal year ended December 31, 2021, filed March 31, 2022. This does not match the request metadata naming Gridai Technologies Corp. Investors should verify the issuer and filing before relying on this summary.
Business context and reporting period
First Wave is a clinical-stage biopharmaceutical company developing gut-restricted therapies for gastrointestinal diseases. Its pipeline includes niclosamide programs and adrulipase for exocrine pancreatic insufficiency. The company acquired First Wave Bio, Inc. in September 2021; consequently, 2021 results include the acquired niclosamide assets and associated costs for only part of the year. The company reported no product revenue in either 2021 or 2020.
Key financial metrics
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense, excluding acquired IP | $17.0 million | $5.9 million |
| Acquired intellectual property expense | $21.3 million | $13.3 million |
| General and administrative expense | $18.4 million | $7.3 million |
| Total operating expenses | $59.1 million | $26.4 million |
| Net loss | $58.5 million | $32.7 million |
| Net loss applicable to common shareholders | $84.5 million | $41.7 million |
| Basic and diluted loss per share | $9.47 | $14.68 |
| Cash used in operating activities | $32.3 million | $11.2 million |
| Cash used in investing activities | $10.3 million | Cash provided: $0.09 million |
| Cash provided by financing activities | $44.8 million | $17.0 million |
| Cash and cash equivalents at year-end | $8.25 million | $6.06 million |
Operating expenses rose substantially, reflecting increased clinical and development activity, acquired-IP charges, and higher public-company, investor-relations and legal costs. The 2021 results also included a $2.35 million impairment of adrulipase-related patents. Interest expense fell to approximately $11,000 from $5.84 million in 2020. No operating margin is meaningful because the company had no revenue.
At December 31, 2021, total assets were $11.8 million and total liabilities were $19.6 million; stockholders’ equity was negative $7.8 million. Current assets of $9.42 million were below current liabilities of $12.30 million, implying negative working capital of approximately $2.88 million. Current liabilities included $8.0 million related to merger consideration; another $7.0 million of merger consideration was classified as long-term. The balance sheet also reported a $641,000 insurance-premium note payable. The filing’s notes separately state negative working capital of $8.0 million, which conflicts with the balance-sheet amounts and MD&A; the filing text does not provide a clear reconciliation.
Material changes and operating developments
- Loss increased to $58.5 million from $32.7 million; operating cash outflow increased to $32.3 million from $11.2 million.
- Research and development expense excluding acquired IP increased by approximately $11.1 million, principally due to clinical trials, niclosamide milestones, manufacturing and regulatory costs.
- Acquisition of First Wave Bio brought niclosamide programs into the company and resulted in $21.3 million of acquired-IP expense. The company recorded a $2.35 million impairment of adrulipase patents.
- Financing in 2021 provided $44.8 million net cash, including ATM sales, registered offerings, preferred-stock proceeds and warrant exercises. Common shares outstanding rose to 14.86 million at year-end from 3.12 million a year earlier; further potential dilution exists from preferred stock, warrants and options.
Outlook, risks and unusual items
- Liquidity and going concern: Management and the auditor reported substantial doubt about the company’s ability to continue as a going concern without additional financing. The company expected continued losses and significant R&D spending. After year-end, the March 2022 offering generated approximately $8.1 million in net proceeds, before any warrant-exercise proceeds.
- Merger payments: A settlement with the former FWB stockholder representative deferred and rescheduled payments, with installments from January 2022 through July 2023 and an aggregate stated payment amount of $17 million. Former FWB stockholders may also be entitled to up to $207 million in contingent development, regulatory and sales milestones, plus specified revenue sharing.
- Listing risk: Nasdaq notified the company that it did not meet the minimum stockholders’ equity requirement. Nasdaq granted an extension through May 25, 2022 to regain compliance; failure to demonstrate compliance could result in delisting.
- Clinical programs: RESERVOIR, a Phase 2 trial of niclosamide for COVID-19 GI infection, completed enrollment in January 2022; no drug-related serious adverse events had been reported, and topline data were expected in the first half of 2022. FW-UP Phase 2 enrollment was underway, with topline data expected by year-end 2022. Adrulipase’s OPTION 2 trial did not consistently meet its primary efficacy endpoint; the company planned a new microgranule formulation and a pilot monotherapy trial in the second half of 2022. PASSPORT for ICI-associated colitis was contingent on sufficient funding.
- Financing and dilution: Series B preferred stock carries a cumulative 9% dividend and exchange rights linked to subsequent financings. February 2022 waivers covered specified holders, but some holders retained exchange rights. The March 2022 offering included common shares and warrants that may substantially increase shares outstanding if exercised.
- Other risks and items: The company relies on outside manufacturers and clinical research organizations, has no approved products or product revenue, and faces clinical, regulatory, supply-chain, COVID-19 and geopolitical risks, including potential disruption from the war in Ukraine. A 2019 cyber-related payment fraud totaled approximately $420,000; approximately $50,000 had been recovered by year-end 2021, with further recovery uncertain.
The auditor issued an unqualified opinion on the financial statements, with an emphasis-of-matter paragraph regarding going concern. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor did not provide an attestation on internal controls.
Most important facts for investors to verify
- Confirm the filing issuer: the document is for First Wave BioPharma, not Gridai Technologies Corp.
- Reconcile the inconsistent negative-working-capital disclosures and review the full going-concern discussion and cash runway assumptions.
- Track Nasdaq compliance and any subsequent listing or delisting developments.
- Confirm the timing, terms and remaining balance of merger installments, milestone obligations and any revenue-sharing commitments.
- Review clinical-trial results as released, especially RESERVOIR, FW-UP and the revised adrulipase formulation program.
- Assess dilution from Series B exchange rights, preferred dividends, outstanding warrants and the March 2022 offering.